UBS upgrades Amneal Pharmaceuticals to Buy with $19 price target

Statements (2)

1. ▲ Bullish

   UBS increased its price target on Celldex Therapeutics, Inc. (CLDX) to $45 from $38 while maintaining a Buy rating.

   finance.yahoo.comJun 30, 2026 13:21 UTC
2. ▲ Bullish

   UBS initiated coverage of Amneal Pharmaceuticals with a Buy rating and set a $19 price target

   finance.yahoo.comMay 1, 2026 08:00 UTC